Matthew Klein
Directeur Général chez PTC THERAPEUTICS, INC.
Fortune : 2 M $ au 30/06/2024
Postes actifs de Matthew Klein
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| CLEARPOINT NEURO, INC. | Directeur/Membre du Conseil | 16/04/2020 | - |
| Independent Dir/Board Member | 16/04/2020 | - | |
| PTC THERAPEUTICS, INC. | Directeur/Membre du Conseil | 22/03/2023 | - |
| Directeur Général | 22/03/2023 | - | |
| President | 22/03/2023 | - | |
| Directeur des opérations | 07/01/2022 | 22/03/2023 | |
| Corporate Officer/Principal | 01/10/2019 | 07/01/2022 | |
| Stanford University | Corporate Officer/Principal | - | - |
| PTC Therapeutics International Ltd. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Matthew Klein
Anciens postes connus de Matthew Klein
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
BioElectron Technology Corp.
 BioElectron Technology Corp. Miscellaneous Commercial ServicesCommercial Services BioElectron Technology Corp. is a clinical-stage biotechnology company, which engages in the research and development of therapeutics for inherited mitochondrial disease. The company was founded in 2005 and is headquartered in Mountain View, CA. | Directeur/Membre du Conseil | 01/01/2018 | 01/01/2020 |
| Directeur Général | 01/01/2018 | 01/01/2019 | |
| Directeur Technique/Scientifique/R&D | 01/01/2012 | 01/01/2019 | |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | Corporate Officer/Principal | - | - |
Edison Pharmaceuticals, Inc.
 Edison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Edison Pharmaceuticals, Inc. developed drugs to treat mitochondrial diseases. It offers EPI-743 and EPI-A0001, an orally absorbed small molecules. The company was founded by Guy Miller in 2005 and was headquartered in Mountain View, CA. | Directeur Technique/Scientifique/R&D | - | - |
Formation de Matthew Klein
| Yale University | Doctorate Degree |
| University of Pennsylvania | Undergraduate Degree |
| UW School of Public Health | Graduate Degree |
Statistiques
Internationale
| Etats-Unis | 10 |
| Irlande | 2 |
Opérationnelle
| Director/Board Member | 4 |
| Corporate Officer/Principal | 3 |
| Chief Tech/Sci/R&D Officer | 2 |
Sectorielle
| Consumer Services | 6 |
| Health Technology | 4 |
| Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| CLEARPOINT NEURO, INC. | Health Technology |
| PTC THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Edison Pharmaceuticals, Inc.
Edison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Edison Pharmaceuticals, Inc. developed drugs to treat mitochondrial diseases. It offers EPI-743 and EPI-A0001, an orally absorbed small molecules. The company was founded by Guy Miller in 2005 and was headquartered in Mountain View, CA. | Health Technology |
BioElectron Technology Corp.
BioElectron Technology Corp. Miscellaneous Commercial ServicesCommercial Services BioElectron Technology Corp. is a clinical-stage biotechnology company, which engages in the research and development of therapeutics for inherited mitochondrial disease. The company was founded in 2005 and is headquartered in Mountain View, CA. | Commercial Services |
| PTC Therapeutics International Ltd. |
- Bourse
- Insiders
- Matthew Klein
- Expérience
